Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved pembrolizumab and berahyaluronidase alfa-pmph, marketed as Keytruda Qlex, for subcutaneous injection for adult and pediatric solid-tumor indications approved for intravenous pembrolizumab.
The approval is not a new checkpoint target. It is a formulation and delivery change that can affect chair time, clinic flow and patient experience.
In oncology operations, delivery route matters because infusion capacity and patient time are real constraints.
Why It Matters
Subcutaneous formulations can make established cancer therapies easier to deliver at scale.
What to Watch
Watch payer treatment, clinic adoption and whether similar formulation shifts spread across oncology portfolios.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAImmunotherapyDrug DeliveryOncology